Boston Scientific Foundation

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

4C Medical Technologies, Inc. is a medical technology company based in Maple Grove, Minnesota, focused on developing minimally invasive therapies for structural heart diseases, particularly mitral regurgitation. The company's primary product, AltaValve, utilizes a unique design that allows for supra-annular positioning and atrial-only fixation, which helps preserve the native mitral valve and left ventricle. This approach aims to eliminate complications associated with traditional transcatheter mitral valve replacement methods that depend on placement and fixation in the native mitral annulus and left ventricle. Founded in 2015, 4C Medical Technologies seeks to provide effective alternatives for patients suffering from mitral regurgitation without the need for valve replacement.

SoniVie is engaged in the development of a medical device aimed at treating pulmonary hypertension through advanced denervation techniques. The company’s device involves a catheter that is inserted into the pulmonary artery during a minimally invasive procedure. This device selectively targets and damages the nerves linked to the disease without affecting the vessel walls or surrounding tissues, allowing physicians to effectively address the condition.

Bolt Medical is a medical device company that specializes in the development of innovative healthcare solutions. Its flagship product is the investigational Bolt IVLTM System, a laser-based intravascular lithotripsy catheter designed for coronary and peripheral interventional procedures. This device offers consistent acoustic output and advantages over existing platforms, potentially improving recovery for patients with moderate to severe calcified arterial disease.

Intera Oncology is focused on enhancing the survival rates of patients with colorectal cancer and cholangiocarcinoma. Established in 2019 and based in Wellesley, Massachusetts, the company has acquired Oncology and Neuromodulation Drug Delivery products from Johnson & Johnson, including accessories for various chemotherapy delivery pumps. Intera Oncology has developed a medical device that features a continuous flow pump designed to deliver chemotherapy directly to the liver, aiming to inhibit the progression of metastases in this organ. Through its innovative approach, the company seeks to improve treatment outcomes and the standard of care for patients battling these challenging cancers.

Cortex is creating an innovative, totally integrated, all-encompassing platform for assessing and treating AFib with precision, simplicity, and speed. The company has formed a proficient team comprising highly skilled and experienced engineers and clinical experts dedicated to introducing this innovative suite of technologies to the market.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation (SNM) systems, catering to both domestic and international markets. The company’s SNM systems are designed to address conditions such as overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its innovative rechargeable SNM System delivers mild electrical pulses to the sacral nerve, aiming to restore normal communication between the brain and the bladder and bowel to alleviate associated symptoms. Originally incorporated as American Restorative Medicine, Inc. in 2012, the company rebranded as Axonics Modulation Technologies, Inc. in August 2013 and is headquartered in Irvine, California.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

Acotec Scientific is an interventional medical device company specializing in solutions for vascular diseases. The company develops a range of products, including drug-coated balloons and percutaneous transluminal angioplasty balloon catheters, aimed at enhancing vascular interventional treatments. One of its key offerings is the semi-compliant PTCA balloon, designed to improve myocardial perfusion by facilitating dilation in coronary arteries or bypass vessels with stenosis. Acotec operates primarily in Mainland China and Europe, along with other regions, generating the majority of its revenue from these markets. The company is committed to innovative treatment approaches that leave nothing behind in the management of vascular conditions.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Obsidio, Inc. is a medical device company founded in 2018 and based in Solana Beach, California. The company specializes in developing shear-thinning hydrogel biomaterial technology, which is used to manufacture therapeutic devices and universal gel embolization materials. This technology allows for minimally invasive procedures to inject embolic materials through catheters, effectively stopping undesirable blood flow in vessels throughout the body. Obsidio's products are applicable in various medical scenarios, including the treatment of hemorrhages, aneurysms, and tumors, as well as managing conditions related to coagulopathy. By focusing on interventional radiology and oncology, Obsidio aims to provide precise and durable solutions for vascular occlusion.

M.I.Tech develops, manufactures, and provides medical devices in the field of digestive endoscopy. It specializes in the fields of manufacturing, medical device and healthcare.

Baylis Medical Company specializes in high-technology medical devices, particularly within cardiology, endovascular, and oncology sectors. The company is renowned for its Radio Frequency Puncture System, which allows for controlled perforations in cardiac and vascular tissues, and is considered the gold standard for treating pulmonary atresia. In addition to developing innovative medical solutions, Baylis Medical has a robust history of importing and distributing products in the Canadian market, representing various manufacturers in cardiology, pain management, and radiology. The company is recognized for its commitment to providing state-of-the-art products and exceptional service, which has fostered a strong reputation within the medical community. Its product offerings include advanced transseptal platforms, guidewires, sheaths, and dilators, aimed at improving safety and efficacy in procedures such as atrial fibrillation ablation and mitral valve interventions.

DeVoro Medical Inc. is a medical device company based in Fremont, California, founded in 2018. The company specializes in developing innovative devices aimed at restoring blood flow, particularly in the peripheral arteries and veins. DeVoro Medical's technology addresses the challenges posed by varying clot morphology and vessel sizes, focusing on the peripheral thrombectomy market. Through its novel flow restoration technology, the company aims to enhance the efficiency of thrombectomy procedures, enabling rapid restoration of blood flow in affected areas of the body.

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, that focuses on treating mid-sized abdominal aortic aneurysms. Founded in 2017, the company has developed an innovative treatment designed to stabilize the growth of aneurysms and prevent their rupture. This treatment delivers a compound containing a stabilizer agent directly to the aneurysm site, which helps inhibit further breakdown and strengthens the vessel wall. By providing a safer intervention option, Nectero Medical aims to enable patients to receive timely care, significantly delaying or preventing the need for major endovascular or surgical repair.

Append Medical is focused on developing a next-generation transcatheter Left Atrial Appendage (LAA) closure system, aimed at preventing strokes by mitigating the risk of blood clot leakage to the brain. Currently in the pre-clinical in-vivo trial phase, the company's innovative approach involves tissue invagination and closure by suture, rather than traditional implants. This method is designed to simplify the treatment of atrial fibrillation while minimizing the presence of foreign materials at the closure site, thereby reducing the risk of device-related thromboembolism. The LAA closure market is anticipated to grow significantly, with estimates suggesting it could reach $25 billion in the coming years. Append Medical is also a participant in MEDX Xelerator, a medtech incubator supported by various industry leaders.

The Lumenis surgical laser division is a global leader in advanced medical laser equipment and surgical laser technology. Lumenis is a pioneer in the field of laser for surgery and its cutting-edge devices are being used by top medical professionals and facilities around the world. The company Provides Urology laser, Gynecology laser, ENT laser and more systems for medical applications.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Farapulse, Inc. develops and commercializes catheter-based tools specifically designed for the treatment of atrial fibrillation. Founded in 2012 and based in Menlo Park, California, the company offers an innovative product known as FARAWAVE, which utilizes advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is available on both catheter and surgical platforms for endocardial and epicardial applications. Farapulse's product range includes various catheter types, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, which enable doctors to isolate pulmonary veins safely and effectively. The company's mission is to enhance the safety, speed, accessibility, and affordability of atrial fibrillation ablation for patients worldwide.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Saluda Medical, established in 2010, is a global medical device company specializing in neuromodulation technologies. Headquartered in Australia with offices in the US and UK, the company develops and commercializes innovative, closed-loop spinal cord stimulation systems. These systems measure and adapt to the spinal cord's response to stimulation, optimizing therapy within each patient's unique therapeutic window. Saluda's primary focus is treating chronic neuropathic pain, with its devices designed to automatically adjust electrical stimulation based on real-time neurophysiological feedback, tailoring treatment to individual patient needs.

InterVene, Inc. is a medical device company based in South San Francisco, California, that specializes in innovative catheter-based therapies for chronic venous insufficiency (CVI), particularly addressing deep vein valve failure. Established in 2011, InterVene has developed the BlueLeaf™ Endovenous Valve Formation System, a non-implantable solution aimed at treating severe venous conditions. The company's devices enable healthcare professionals to create new vein valves from the patient's own vein wall tissue, improving blood flow from the legs back to the heart. By focusing on minimally invasive treatments, InterVene seeks to enhance patient outcomes for those suffering from venous stasis ulcers and associated symptoms.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

Cryterion Medical is focused on developing a single-shot cryoablation platform aimed at treating atrial fibrillation (AF). Headquartered in Carlsbad, California, with additional offices in Montreal, Canada, and Wexford, Ireland, the company’s innovative platform employs cryothermal energy to disrupt irregular electrical signals that lead to AF. The system features a next-generation balloon catheter, advanced mapping catheter, steerable sheath, and an enhanced console, all designed to improve procedural workflow and maneuverability, particularly in complex anatomical situations. This technology enables physicians to effectively target and treat the areas of the heart responsible for abnormal rhythms, enhancing the overall treatment of atrial fibrillation.

RenovoRx, Inc. is a medical device company based in Los Altos, California, established in 2012. It focuses on developing innovative solutions for the targeted delivery of therapeutic and diagnostic agents to specific sites within the peripheral vascular system. The company's flagship product, the RenovoCath, is designed for use in the visceral and peripheral vascular systems and has received FDA clearance for clinical use. RenovoRx aims to enhance therapeutic outcomes for cancer patients through its proprietary Trans-Arterial Micro-Perfusion therapy platform, which allows for precise delivery of treatments directly to tumors while potentially reducing systemic side effects. The company is supported by a dedicated management team and an advisory board composed of experts in interventional radiology, surgical oncology, and gastroenterology, providing guidance for its clinical development strategies.

nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

NxThera, Inc. is a medical technology company based in Maple Grove, Minnesota, established in 2008 and currently a subsidiary of Boston Scientific Corporation. The company specializes in convective water vapor energy technology aimed at treating endourological conditions, particularly benign prostatic hyperplasia (BPH), which affects over 32 million men in the United States. NxThera's innovative platform employs a minimally invasive vapor therapy that converts sterile water into thermal energy delivered to prostate tissue, providing an effective treatment option for patients suffering from urologic conditions, including prostate and kidney cancer. This approach aims to enhance urinary flow and improve overall patient quality of life while minimizing side effects commonly associated with traditional treatments.

EMcision Ltd. was a medical device company focused on developing proprietary devices utilizing radiofrequency (RF) technology to aid the surgical community and improve the lives of cancer patients. The company's product lineup included various bipolar RF probes and catheters designed for specific applications, such as the Habib EndoHPB for ablation in the gastrointestinal tract and the Habib Endoblate for endoluminal ablation of inoperable gastrointestinal tumors. Other notable devices included the Habib VesCoag for precise vascular occlusion and the Habib 3Fr PerCoag for percutaneous ablation of solid tumors. EMcision marketed its products through a direct sales force in the United States and a network of distributors across numerous countries, including Canada, Germany, and the United Kingdom. Founded in 1999 and based in London with an office in Montreal, the company aimed to enhance cancer treatment options until it ceased operations.

Millipede Inc. is a medical technology company based in Santa Rosa, California, focused on developing catheter-based solutions for the treatment of mitral and tricuspid regurgitation. Founded in 2012, the company designs a semi-rigid annuloplasty ring that aims to replicate the gold standard in valve repair. This innovative solution helps restore the health of patients by reducing the valve annulus diameter, which facilitates the return of leaflet coaptation and alleviates severe mitral regurgitation. As of early 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, expanding options for physicians and patients globally.

Millipede Inc. is a medical technology company based in Santa Rosa, California, focused on developing catheter-based solutions for the treatment of mitral and tricuspid regurgitation. Founded in 2012, the company designs a semi-rigid annuloplasty ring that aims to replicate the gold standard in valve repair. This innovative solution helps restore the health of patients by reducing the valve annulus diameter, which facilitates the return of leaflet coaptation and alleviates severe mitral regurgitation. As of early 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, expanding options for physicians and patients globally.

Apama Medical, Inc. is a medical device company based in Campbell, California, specializing in catheter ablation technology for the treatment of atrial fibrillation (AF). Established in 2009, the company has developed an innovative radiofrequency (RF) balloon catheter system that integrates multiple electrodes and combines the advantages of both RF point-by-point and balloon-based ablation techniques. This system features built-in digital cameras, LED lights, and sensing electrodes, allowing for real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical aims to enhance the detection and treatment of heart rhythm disorders, ultimately enabling shorter procedure times and improved patient outcomes. As of October 2017, Apama Medical operates as a subsidiary of Boston Scientific Corporation.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Amphora Medical, Inc. is a Minnesota-based company that develops medical devices aimed at treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is focused on creating a novel cystoscopic device designed to enhance bladder function and improve the quality of life for individuals suffering from this condition. Utilizing minimally invasive procedures, Amphora Medical's innovative technology has the potential to offer significant benefits to patients dealing with OAB.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Neovasc Inc. is a specialty medical device company based in Richmond, Canada, focused on the development, manufacturing, and marketing of products for the cardiovascular marketplace. The company offers innovative solutions, including the Tiara technology for the transcatheter treatment of mitral valve disease and the Neovasc Reducer, designed for the treatment of refractory angina. The Reducer has been commercially available in Europe since 2015, although it is not yet available in the United States. The Tiara device is currently under clinical investigation across multiple regions, including the United States, Canada, and Europe. Neovasc's expertise also extends to pericardial tissue processing and vascular product development, providing comprehensive design and manufacturing solutions to industry partners. Founded in 2000 and originally known as Medical Ventures Corp., Neovasc has positioned itself within a rapidly growing market, focusing on advanced medical technologies to address complex cardiovascular conditions.

The LumenR Tissue Retractor System is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach.

EndoChoice is a medical technology company specializing in the design and commercialization of products and services for gastrointestinal (GI) care. Headquartered in Alpharetta, Georgia, EndoChoice offers a comprehensive range of products, including single-use devices, infection control solutions, diagnostics, and advanced imaging systems. The company's proprietary product portfolio features the Full Spectrum Endoscopy™ System, known as Fuse™, which includes colonoscopes and gastroscopes equipped with multiple imagers. This innovative system enables physicians to achieve a 330-degree field of view, significantly improving the detection of polyps compared to traditional endoscopes. With a direct sales organization serving over 2,000 customers in the United States and partnerships with 34 distributors globally, EndoChoice has established a strong presence in the market. Founded in 2008, the company experienced rapid growth and was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. before its acquisition by Boston Scientific in 2016.

Securus Medical Group engages in the development of clinical tools to improve the safety and efficacy of ablation therapy by providing real-time, non-contact, high-resolution tissue temperature monitoring, and mapping products. The company engages in developing real-time, noncontact, thermal mapping systems to determine intrabody tissue temperatures.

Cosman Medical specializes in the development and manufacturing of radiofrequency (RF) ablation systems, including RF generators, electrodes, and cannulae, aimed at neurosurgery and pain management. With over 60 years of proven effectiveness, RF nerve ablation technology is utilized to alleviate various chronic pain conditions, including back and neck pain, sciatica, and headaches, as well as severe pain associated with end-stage cancer and other complex pain syndromes. In the field of podiatry, Cosman Medical's products address intractable pain related to foot, heel, and ankle disorders such as plantar fasciitis. Additionally, the company’s offerings extend to functional neurosurgery, where RF technology is used to manage movement disorders like Parkinson's Disease and essential tremor.

NxThera, Inc. is a medical technology company based in Maple Grove, Minnesota, established in 2008 and currently a subsidiary of Boston Scientific Corporation. The company specializes in convective water vapor energy technology aimed at treating endourological conditions, particularly benign prostatic hyperplasia (BPH), which affects over 32 million men in the United States. NxThera's innovative platform employs a minimally invasive vapor therapy that converts sterile water into thermal energy delivered to prostate tissue, providing an effective treatment option for patients suffering from urologic conditions, including prostate and kidney cancer. This approach aims to enhance urinary flow and improve overall patient quality of life while minimizing side effects commonly associated with traditional treatments.

TVA Medical, Inc. is a medical device company based in Austin, Texas, focused on developing catheter-based solutions for end-stage renal disease and peripheral vascular diseases. Founded in 2009, the company specializes in innovative, minimally invasive therapies, notably through its everlinQ endoAVF system. This system facilitates the creation of an arteriovenous fistula using an endovascular approach, allowing for hemodialysis in patients with kidney failure. This method is designed to be less invasive than traditional surgical techniques, resulting in reduced trauma to blood vessels. TVA Medical operates as a subsidiary of Becton, Dickinson and Company and has received funding from Santé Ventures.

Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

American Medical Systems, a subsidiary of Endo Pharmaceutical based in Minnetonka, Minnesota, specializes in medical devices and procedures aimed at treating incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse, and other pelvic disorders affecting both men and women. These conditions can severely impact an individual's quality of life and social interactions. In recent years, there has been a notable increase in the number of patients seeking treatment due to longer life expectancies, heightened expectations for quality of life, and increased awareness of available treatment options. The company's offerings focus on reducing or eliminating the debilitating effects of these disorders, frequently utilizing minimally invasive therapies. In 2010, American Medical Systems' products were utilized to treat over 340,000 patients.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.

InterVene, Inc. is a medical device company based in South San Francisco, California, that specializes in innovative catheter-based therapies for chronic venous insufficiency (CVI), particularly addressing deep vein valve failure. Established in 2011, InterVene has developed the BlueLeaf™ Endovenous Valve Formation System, a non-implantable solution aimed at treating severe venous conditions. The company's devices enable healthcare professionals to create new vein valves from the patient's own vein wall tissue, improving blood flow from the legs back to the heart. By focusing on minimally invasive treatments, InterVene seeks to enhance patient outcomes for those suffering from venous stasis ulcers and associated symptoms.

Iogyn, Inc. is a medical device start-up company located in Cupertino, California. The Company has developed the Symphion System, designed for endoscopically-controlled Radiofrequency bi-polar resection and removal of soft tissue, such as polyps, myomas and prostate adenomas, requiring endoscopic visualization under continuous flow conditions.

StarMedTec is an internationally recognized manufacturer of medical laser systems, specializing in the development, production, and marketing of laser technologies. The company offers solutions that cater to various medical fields, including urology, gynecology, gastroenterology, ENT, pneumology, and general surgery. By focusing on the integration of laser systems with its existing portfolio of urology devices, StarMedTec aims to enhance surgical outcomes and provide innovative treatment options for healthcare professionals.

Sensible Medical Innovation Ltd, established in 2007 and based in Netanya, Israel, specializes in developing medical radar technology for monitoring and imaging. The company's flagship product, ReDS, is designed to track and manage lung fluid in patients with heart failure and other fluid-related health issues, providing accurate and actionable data to healthcare professionals. This non-invasive solution aims to enhance patient care, improve quality of life, and potentially reduce hospital readmissions.

SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

BaroSense is focused on developing and commercializing innovative medical devices aimed at addressing obesity, a significant healthcare challenge in the United States. The company aims to provide safe, simple, and effective alternatives to surgical treatments for obesity, catering to individuals who require assistance beyond traditional dieting methods and wish to avoid extensive and irreversible surgical options. BaroSense's product offerings include minimally invasive therapeutic procedures and devices, such as a trans-oral endoscopic restrictive implant system, designed to facilitate weight loss in a less invasive manner.

Bard Electrophysiology, a division of C. R. Bard, Inc., specializes in the development and delivery of devices for diagnosing and treating cardiac arrhythmias. With a comprehensive product portfolio, the company provides advanced radiofrequency (RF) ablation and mapping catheters, diagnostic catheters, and computer-based electrophysiology mapping and recording systems. Additionally, Bard Electrophysiology offers temporary pacing electrodes and vascular/cardiac access devices. Through its commitment to innovation and education, Bard Electrophysiology has established itself as a leader in the electrophysiology field, supporting healthcare providers in managing complex cardiac conditions.

Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Vessix Vascular, Inc., previously known as Minnow Medical, Inc., is a privately-held company focused on developing innovative medical devices using radiofrequency balloon catheter technology. The company's primary product, the ZCath® System, has received a CE Mark, allowing its use in reducing plaque in peripheral leg arteries. Additionally, Vessix Vascular is working on a catheter-based device aimed at treating high blood pressure by targeting and deadening nerves near the kidneys. As a pre-revenue stage enterprise, Vessix Vascular is positioned to address significant medical needs in vascular health and hypertension management.

Rhythmia Medical, Inc. is an early-stage medical device company specializing in the development of technologies for the treatment of cardiac arrhythmias. The company is particularly focused on creating an advanced 3D mapping system designed to enhance catheter ablation procedures for tachy-arrhythmias, including atrial fibrillation. This innovative system aims to improve visualization and navigation during these medical procedures, ultimately seeking to provide more effective treatment options for patients suffering from these conditions.

BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Intelect Medical, Inc. is an early-stage medical device company that specializes in the development and commercialization of deep brain stimulation (DBS) therapies for patients affected by disabilities resulting from stroke and traumatic brain injury. The company is dedicated to creating an implantable neuromodulation system aimed at enhancing recovery outcomes for individuals dealing with the long-term effects of these conditions. By focusing on innovative solutions in neuromodulation, Intelect Medical seeks to improve the quality of life for patients facing significant health challenges.

Sadra Medical is focused on developing innovative therapies for the treatment of aortic valve disease, particularly through minimally invasive alternatives to traditional surgical valve replacement. The company offers transcatheter aortic valve replacement systems, including the Lotus valve, which is a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure. Additionally, Sadra Medical provides the Lotus delivery catheter, designed for the guidance and placement of the Lotus valve. With aortic valve stenosis affecting approximately 3 million people in the U.S. and a significant portion remaining untreated, Sadra Medical aims to address this unmet clinical need by enhancing treatment options and improving patient care while reducing the risks associated with open-heart surgery.

Asthmatx, Inc. is a medical device company based in Mountain View, California, that specializes in the development and commercialization of therapeutic treatments for asthma. Founded in 2003, the company has created a technology that delivers controlled thermal energy to the airways of adult patients, aimed at reducing the mass of airway smooth muscle through a procedure known as Bronchial Thermoplasty. Asthmatx offers the Alair System, an interventional medical device designed for bronchoscopic treatment of patients suffering from moderate to severe asthma. As of October 2010, Asthmatx operates as a wholly-owned subsidiary of Boston Scientific.

Sadra Medical is focused on developing innovative therapies for the treatment of aortic valve disease, particularly through minimally invasive alternatives to traditional surgical valve replacement. The company offers transcatheter aortic valve replacement systems, including the Lotus valve, which is a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure. Additionally, Sadra Medical provides the Lotus delivery catheter, designed for the guidance and placement of the Lotus valve. With aortic valve stenosis affecting approximately 3 million people in the U.S. and a significant portion remaining untreated, Sadra Medical aims to address this unmet clinical need by enhancing treatment options and improving patient care while reducing the risks associated with open-heart surgery.

Intelect Medical, Inc. is an early-stage medical device company that specializes in the development and commercialization of deep brain stimulation (DBS) therapies for patients affected by disabilities resulting from stroke and traumatic brain injury. The company is dedicated to creating an implantable neuromodulation system aimed at enhancing recovery outcomes for individuals dealing with the long-term effects of these conditions. By focusing on innovative solutions in neuromodulation, Intelect Medical seeks to improve the quality of life for patients facing significant health challenges.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflicted individual and advances it into the heart. Once it reaches the targeted cardiac tissue, the catheter tip temperature is lowered to approximately -90°C — thereby blocking the conduction of the abnormal signals causing the heart to beat inappropriately and restoring its function to normal. The CryoCor™ Cardiac Cryoablation System consists of a cryoablation catheter that is connected to an articulating arm mounted on the company’s refrigeration console. To facilitate catheter placement, the System can be used in conjunction with CryoCor introducer sheaths. The System has been approved for use in Europe and has been commercially available there since 2002. CryoCor's European activities are managed by its wholly-owned subsidiary in Cologne, Germany which directs the company's marketing, sales and post-market clinical activities. The CryoCor Cardiac Cryoablation System is currently in use at multiple medical centers throughout Europe.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.

Intelect Medical, Inc. is an early-stage medical device company that specializes in the development and commercialization of deep brain stimulation (DBS) therapies for patients affected by disabilities resulting from stroke and traumatic brain injury. The company is dedicated to creating an implantable neuromodulation system aimed at enhancing recovery outcomes for individuals dealing with the long-term effects of these conditions. By focusing on innovative solutions in neuromodulation, Intelect Medical seeks to improve the quality of life for patients facing significant health challenges.

ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlying course of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients.

EndoTex Interventional Systems, Inc. is a development stage medical device company based in Cupertino, California, founded in 1995. The company specializes in creating less-invasive medical devices aimed at addressing conditions within the vascular system, with a particular focus on treating carotid artery disease. EndoTex is recognized for its innovative interventional vascular therapeutic solutions. As of January 2007, it operates as a subsidiary of Boston Scientific Corp.

Health Hero Network, Inc. specializes in developing technology solutions for remote health monitoring and management, primarily aimed at enhancing communication between patients and healthcare providers. The company offers a comprehensive Health Buddy system that facilitates patient education and chronic condition monitoring, integrating various technologies and clinical information databases. Its services cater to a diverse clientele, including hospitals, health plans, government health organizations, disease management firms, and pharmaceutical companies involved in clinical trials. Founded in 1988 and based in Palo Alto, California, Health Hero Network operates as a subsidiary of Robert Bosch GMBH, focusing on delivering personalized health management programs that enable providers to effectively monitor patient health and make informed decisions.

Sadra Medical is focused on developing innovative therapies for the treatment of aortic valve disease, particularly through minimally invasive alternatives to traditional surgical valve replacement. The company offers transcatheter aortic valve replacement systems, including the Lotus valve, which is a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure. Additionally, Sadra Medical provides the Lotus delivery catheter, designed for the guidance and placement of the Lotus valve. With aortic valve stenosis affecting approximately 3 million people in the U.S. and a significant portion remaining untreated, Sadra Medical aims to address this unmet clinical need by enhancing treatment options and improving patient care while reducing the risks associated with open-heart surgery.

Solace Therapeutics, Inc. is a medical device company focused on developing non-surgical treatments for common bladder disorders, including stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company offers the Vesair Bladder Control System, a lightweight device designed to float within the urinary bladder and effectively reduce involuntary urinary leakage. Solace Therapeutics aims to enhance patient quality of life by providing an office-based therapy that avoids the side effects often associated with traditional drug and surgical options. This innovative approach does not require anesthesia or significant lifestyle changes and is reversible at any time. Established in 2002, Solace Therapeutics is headquartered in Framingham, Massachusetts.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Guidant Corporation specializes in the design and manufacture of medical devices for cardiovascular care. Operating as part of Boston Scientific and Abbott Labs, the company focuses on products for cardiac-rhythm management and the treatment of coronary artery disease. Its offerings include artificial cardiac pacemakers, implantable cardioverter-defibrillators, stents, catheters, and devices for heart-failure therapy. Headquartered in Indianapolis, Indiana, Guidant aims to improve the quality of life for patients with heart diseases and enhance clinical outcomes for physicians. Founded in 1994, the company has established itself as a key player in the cardiovascular medical device industry.

Cameron Health, Inc. is a development-stage medical device company focused on creating advanced implantable electronic devices aimed at improving patient care in the field of cardiac health. The company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems designed for patients at risk of life-threatening ventricular tachyarrhythmias. Their product line includes the SQ-RX pulse generator, which is essential for managing cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, designed for optimal placement within the body. Additionally, the Q-TECH programmer enables wireless communication with the SQ-RX device, enhancing device functionality. Cameron Health's mission is to address unmet medical needs through innovative technology, leveraging the expertise of its team to tackle complex medical challenges.

Adiana, Inc. is a medical device company based in Redwood City, California, that specializes in the development of permanent contraceptive solutions for women. Founded in 1997, the company focuses on transcervical sterilization systems designed to prevent pregnancy by occluding the fallopian tubes. Its flagship product, Complete TCS, includes a radiofrequency generator, a delivery catheter, and an implantable matrix. This innovative approach offers a non-incisional alternative to traditional tubal ligation, allowing women to avoid the potential side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.

BrainsGate, Ltd. is a medical device company based in Caesarea, Israel, specializing in therapies for patients with central nervous system diseases. The company has developed a technology platform that utilizes electrical stimulation of the spheno-palatine ganglion (SPG) to enhance cerebral blood flow. Currently, BrainsGate is focused on treating acute ischemic stroke through its innovative ischemic stroke system, which involves a miniature electrode implanted in the roof of the mouth during a minimally invasive procedure. This method is performed under local anesthesia and is comparable to standard dental treatments. The company has conducted several clinical trials, including a pivotal trial with 300 patients that validated the safety and efficacy of its treatment. BrainsGate is also engaged in a multi-national, randomized study known as ImpACT-24b, aimed at further assessing the effectiveness of its approach within a critical 24-hour window following a stroke.

3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

CryoVascular Systems, based in Los Gatos, California, specializes in developing and manufacturing medical technology for the treatment of peripheral vascular and cardiovascular diseases. The company's primary product, the PolarCath Peripheral Dilatation System, employs a proprietary technology that utilizes liquid nitrous oxide to achieve precise cooling of diseased arteries during balloon angioplasty, a procedure known as CryoPlasty. This innovative approach aims to revascularize the artery while significantly reducing the post-procedure rate of restenosis, a condition that often necessitates repeat angioplasty or surgical interventions. The prevalence of restenosis in patients treated with conventional balloon angioplasty and stenting techniques is notably high, reported at 30-40 percent for femoral-popliteal arteries. CryoVascular Systems was incorporated in 1997 and became part of Boston Scientific Corporation in 2005.

Advanced Stent Technologies designs and develops stents and stent delivery systems for the treatment of atherosclerosis at bifurcations in the coronary vasculature. The company’s flagship product, the SLK-View stent and delivery system, is used for treating diseased bifurcations by providing stability to the main artery while maintaining access to the side branch vessel. Advanced Stent Technologies was founded in 1997 and is based in Pleasanton, California.

VisionCare Ophthalmic Technologies, Inc. is a specialty medical device company based in Saratoga, California, focused on the research, development, manufacture, and marketing of innovative implantable ophthalmic devices. The company primarily aims to enhance vision and quality of life for individuals suffering from untreatable retinal disorders, particularly end-stage age-related macular degeneration (AMD), which is a leading cause of blindness among older Americans. VisionCare's flagship product is the Implantable Miniature Telescope, the first FDA-approved device designed to improve vision in patients with advanced AMD. This telescope implant is a critical component of the CentraSight treatment program, which guides patients through the processes of diagnosis, surgical evaluation, and postoperative care. Founded in 1997, VisionCare is dedicated to helping patients reconnect with their daily lives and activities through its advanced visual prosthetic technologies.

REVA Medical, Inc. is a medical device company specializing in the development and commercialization of polymer-based bioresorbable products for vascular applications. The company focuses on innovative solutions for coronary artery disease and peripheral artery disease, offering its lead products: the Fantom Encore, a bioresorbable vascular scaffold for coronary artery treatment, and the MOTIV scaffold for below-the-knee applications. These products are designed to support the artery during the healing process and subsequently dissolve, restoring natural artery function. REVA Medical markets its Fantom Encore product in several European countries, including Germany, Austria, and Italy. Founded in 1998 and headquartered in San Diego, California, REVA Medical aims to improve patient health through the use of advanced biomaterials in implantable medical devices.

3F Therapeutics develops, manufactures, and markets cardiovascular devices. It offers invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system to reduce surgical cross-clamp and cardio-pulmonary bypass time, utilization for congestive heart failure.

Advanced Bionics Corporation, founded in 1993 and headquartered in Valencia, California, specializes in the development and manufacturing of advanced cochlear implants and implantable neurostimulation devices. The company focuses on restoring hearing for the deaf and alleviating chronic pain through its innovative technologies. With additional offices in Rixheim, France, and Tokyo, Japan, Advanced Bionics is committed to improving the quality of life for individuals with hearing impairments and neurological conditions by delivering targeted therapies using electrical stimulation.